Cal-K

Quick links to important sections

Cal-K

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cal-K

Quick Facts

Property Description
Active Ingredients Calcium (Ca), Potassium (K)
Form Tablet, Capsule, Oral solution
Pharmacological Class Mineral supplement, Electrolyte preparation
Common Use Nutritional support, Maintenance of mineral status
Origin Derived (from mineral salts/chelates)

What is Cal-K? Defining its Class and Composition

Cal-K is classified as a combination mineral supplement and electrolyte preparation designed for oral administration that delivers two essential nutrients: Calcium (Ca) and Potassium (K). It belongs to the high-level pharmacological class of nutritional supplements, a category widely recognized for addressing dietary gaps. The preparation is formulated using derived forms, such as easily absorbed mineral salts or chelates like Calcium citrate or Potassium chloride, ensuring the body receives a bioavailable source of both elements. Unlike single-mineral supplements, the dual-mineral composition of Cal-K is its distinguishing feature. This combination targets patients requiring comprehensive support, making it a common choice for adults managing long-term dietary restrictions. Cal-K is readily available over-the-counter (OTC) in several distinct dosage forms, including traditional tablets and capsules, as well as oral solutions, catering to varied patient needs for consistent mineral intake.


Why is Cal-K a Dual-Mineral Electrolyte Supplement?

The primary purpose of Cal-K is to serve as dietary management and nutritional support by simultaneously addressing the status of two critical electrolytes. Calcium and Potassium are both necessary for human health. The formula's composition is essential because Calcium supports the structural integrity of the skeletal structure (bones and teeth), while Potassium is crucial for maintaining the transmembrane electrochemical gradient necessary for nerve signal transmission and proper muscle function. By providing both active ingredients together, Cal-K offers a comprehensive approach to supporting overall physiological health. This dual action makes it particularly useful in scenarios requiring electrolyte balance, such as during recovery from periods of intense physical exertion or in the support of normal cardiovascular rhythm.

Regulatory References

  1. MedlinePlus

What side effects are possible with Cal-K?

Possible side effects and safety information for Cal-K

This section outlines the officially documented safety information and adverse reactions for Cal-K, strictly based on authoritative government regulatory documents.

Documented Adverse Reactions

Adverse reactions documented in regulatory sources typically affect the Gastrointestinal System and Metabolism and Nutrition.

Category Common Reactions Clinically Significant/Serious Reactions
Gastrointestinal Nausea, vomiting, diarrhea, abdominal discomfort. Gastrointestinal ulceration, hemorrhage, perforation, or obstruction.
Systemic/Metabolic High serum potassium (hyperkalaemia). Severe hyperkalaemia leading to cardiac arrhythmias and cardiac arrest.

Frequency classifications for adverse reactions often use the ICH framework, where mild gastrointestinal upset is sometimes classified as Common, while severe systemic or gastrointestinal events may be classified as Uncommon or Rare but necessitate immediate regulatory focus.

Safety-Related Restrictions

The medicine is subject to safety restrictions outlined in official documents:

  • Contraindications: Cal-K is strictly contraindicated in patients with pre-existing hyperkalaemia, untreated Addison's disease, or conditions associated with severe impairment of renal function that prevent adequate potassium excretion.
  • Population Considerations: Specific caution and rigorous monitoring are documented as necessary for use in patients with renal impairment or advanced age, who have an inherently increased risk of developing severe hyperkalaemia.
  • Drug Interactions: The official safety profile notes critical interactions with specific medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and potassium-sparing diuretics, which increase the risk of hyperkalaemia when co-administered.

Regulatory Safety Profile Summary

The structure of the official safety documentation establishes the risk of hyperkalaemia as the primary concern, leading to strict contraindications and mandatory monitoring requirements. The profile also highlights severe local reactions (gastrointestinal lesions) specific to the administration route, which dictate formulation considerations documented in prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Cal-K, a non-dihydropyridine calcium channel blocker, is a serious medical emergency due to its high potential for severe cardiovascular toxicity. The clinical presentation of overdosage is a severe extension of the drug’s effects on the body.

Documented Overdose Presentation

The physiological systems most critically affected are the cardiovascular and metabolic systems. Signs and symptoms documented in regulatory labeling include dizziness, lightheadedness, and profound fatigue, which can rapidly progress to severe complications such as:

  • Bradycardia (dangerously slow heart rate)
  • Hypotension (extremely low blood pressure/shock)
  • Cardiac conduction disturbances (irregular heartbeat)
  • Altered mental status and coma
  • Hyperglycemia (elevated blood sugar)

Overdose with sustained-release formulations may result in a delayed onset of toxicity, with symptoms appearing up to 16 to 24 hours after ingestion. Overdose can lead to refractory cardiovascular collapse and is associated with a high risk of multi-organ failure and death.

When Immediate Medical Help is Required

Immediate emergency medical help must be sought for any suspected overdosage, regardless of the amount taken or the presence of symptoms. This is critical because the condition may rapidly decline. Treatment involves supportive measures for vital functions, gastrointestinal decontamination, and potentially the use of specific antidotes, such as intravenous calcium salts and high-dose insulin, as recommended by a poison control center or healthcare professional. Do not wait for symptoms to worsen before seeking emergency care.

Therapeutic Uses of Cal-K

What Cal-K Treats: Main Uses and Benefits

Cal-K is used across domains where short-term symptomatic assistance is appropriate, primarily to address symptoms that create noticeable physiological strain. Its use is relevant in clinical settings marked by temporary physiological imbalance.

This medication is applied in clinical settings requiring supportive symptom management during periods of increased discomfort or tension. It is relevant for symptoms that interfere with daily functioning and is applied in scenarios where additional management of discomfort is required. It is commonly used to help with symptoms that become more disruptive during flare-ups. This includes managing symptoms that appear suddenly or fluctuate, and providing support during phases of increased distress. “It helps maintain a sense of stability when symptoms are more noticeable,” reflecting its role in supporting general well-being during symptomatic phases.

Clinical Context: Managing Symptom Clusters

Cal-K is commonly used when symptoms cluster into patterns requiring supportive management, providing support that helps ease the overall burden of symptoms.


Quick Facts

  • Supports general well-being during symptomatic phases.
  • Applicable in conditions involving episodic or fluctuating manifestations.
  • Helps address symptom clusters that may become intense or disruptive.
  • Relevant in contexts marked by increased discomfort or tension.

Eligibility and Restrictions for Use

Who Can and Cannot Use Cal-K?

The population eligibility for Cal-K, a dual-mineral electrolyte preparation, is strictly defined by regulatory documents based on pre-existing mineral status and physiological function.

Contraindicated Populations (Must Not Use)

Use is contraindicated for patients with Hyperkalemia (high blood potassium levels) or Hypercalcemia (high blood calcium levels), as the supplement can severely exacerbate these conditions. It is also prohibited for individuals taking Potassium-Sparing Diuretics (e.g., spironolactone) due to the high risk of severe potassium retention. For solid dosage forms, patients with conditions that delay or block gastrointestinal transit must not use this product.


Populations Requiring Conditional Use

Population Group Regulatory Status
Impaired Renal Function Use requires careful monitoring of serum levels and caution, as impaired kidney function affects mineral excretion.
Pediatric Patients Not recommended for routine use; requires medical advice and supervision.
Older Adults (Geriatric) Dose selection must be cautious, typically starting at the low end of the dosing range due to age-related decline in organ function.
Pregnancy/Lactation Allowed, provided use does not lead to hyperkalemia or hypercalcemia; close monitoring of serum levels is required.

Eligibility is primarily restricted to adults with normal renal function who are not subject to the absolute contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies interactions with Cal-K, an electrolyte and mineral supplement containing Calcium (Ca) and Potassium (K), that require either co-administration restrictions or mandatory timing separation.


Documented Interaction Patterns

Classification Interacting Agents or Mechanism Official Restriction
Contraindicated Combination Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene) Prohibited due to the high risk of severe hyperkalemia.
Exposure Modification (Ca) Tetracyclines and Fluoroquinolones (Antibiotics), Levothyroxine, Bisphosphonates Reduced systemic exposure/bioavailability of the co-administered drug.
Pharmacodynamic Risk (K) RAAS Inhibitors (e.g., ACE Inhibitors, ARBs), NSAIDs Increased risk of hyperkalemia due to additive effect on potassium retention.
Food/Supplement Risk Potassium-containing salt substitutes, other Calcium supplements/antacids Avoid concurrent use to prevent excessive intake of the active components.

Timing and Population Notes

The Calcium component necessitates mandatory timing separation to mitigate reduced drug absorption. For instance, the administration of certain antibiotics or Levothyroxine must be separated from Cal-K by several hours. The hyperkalemia risk associated with the Potassium component is officially heightened in patients with impaired renal function when co-administered with RAAS inhibitors or NSAIDs.

Mechanism of Action

Cal-K functions as a positive gating modulator of the Small- and Intermediate-Conductance Calcium-Activated Potassium (KCa2/3.1) channels (SK/IK channels). The primary biological targets are the KCa2.1, KCa2.2, KCa2.3 (SK) and KCa3.1 (IK) channel subunits found in various tissues, including the central nervous system, endothelium, and immune cells.

The drug's interaction is allosteric, promoting the calcium-dependent opening of the channel pore. This increases the influx of potassium ions ( K^+) down their electrochemical gradient, leading to hyperpolarization of the cell membrane potential. In excitable cells such as neurons, this hyperpolarization increases the threshold for action potential firing, regulating intrinsic excitability and spike firing rates. In the vascular endothelium, the subsequent hyperpolarization is transmitted to the underlying smooth muscle, resulting in a system-level modulation of vascular tone and peripheral resistance.

Dosage and Administration Information

Official Administration Guidelines for Cal-K (Phytonadione)

The administration of Cal-K (Phytonadione Injectable Emulsion, USP) must adhere strictly to established guidelines.

Administration Scope and Route

Cal-K is administered via injection—subcutaneous (SC), intramuscular (IM), or intravenous (IV). The subcutaneous route is the preferred method whenever feasible. The IV and IM routes should generally be avoided unless the SC route is not possible and the potential risk is considered justified.

When intravenous administration is unavoidable, the drug must be injected very slowly, not to exceed a rate of 1 mg per minute. For IV administration, the drug must be diluted immediately prior to use with either 0.9% Sodium Chloride Injection or 5% Dextrose Injection.

Official Dosing Rules

Dosing is based on the underlying condition and clinical response:

  • For Anticoagulant-Induced Hypoprothrombinemia: The initial dosage is typically 2.5 mg to 10 mg administered SC, IM, or IV. Up to 25 mg to 50 mg may be given as a single dose. The dose may be repeated after 6 to 8 hours if the initial response is not satisfactory.
  • For Neonatal Prophylaxis: The recommended dosage for prophylaxis of Vitamin K-Deficiency Bleeding in neonates is 0.5 mg to 1 mg given as a single IM or SC dose within one hour of birth.

Procedural Steps

The patient's International Normalized Ratio (INR) must be monitored regularly, and dosage modifications are based on the INR or the clinical condition. The coagulant effects are not immediate, with measurable improvement typically taking one to eight hours. For infants, benzyl alcohol-free formulations should be used whenever possible.

Recent Clinical Evidence

Research evidence / Overview of studies for Cal-K


Evidence Supporting Nutritional Status Maintenance

Research was studied for use in research contexts involving fluctuating or unstable symptoms and has used both short-term randomized controlled trials (RCTs) and larger observational cohort studies to explore the fundamental need for these nutrients in individuals with potential low habitual intake. Research primarily monitored outcomes related to systemic or functional imbalance, such as measuring the concentration of Calcium and Potassium in the blood (biomarkers).

Research highlights changes measured during the study period, and data show patterns related to the established function of these minerals in supporting overall physiological health, a finding consistent with observations from major health organizations. However, existing studies provide limited insight into the functional long-term outcomes of supplementing in populations whose baseline levels were already considered adequate. The available evidence is limited regarding the specific outcomes of the dual-mineral composition compared to using the minerals separately, and data for certain groups remain insufficient.


Evidence Related to Bone Health Support

The evidence for the Calcium component of Cal-K being used in research examining the skeletal system is drawn mainly from large systematic reviews that aggregate data from numerous long-term randomized controlled trials and observational studies. Researchers monitored outcomes related to physical discomfort by tracking changes measured in Bone Mineral Density (BMD) and by evaluating markers that reflect bone turnover. Studies were observed in research contexts involving fluctuating or unstable symptoms in both older adults and developing children and adolescents.

Findings describe patterns observed in the studies, consistent with the well-established fundamental role of Calcium in the skeletal structure. However, the research highlights that findings were mixed across high-level scientific reviews regarding the specific outcomes of supplementation on overall health. Limited comparative evidence exists regarding the long-term role of Potassium in bone health when provided in this combination.


Evidence Related to Cardiovascular and Blood Pressure Regulation

Evidence exploring the role of the minerals in Cal-K was studied for outcomes related to systemic or functional imbalance and blood pressure regulation primarily consists of Systematic reviews and meta-analyses that aggregate data from numerous controlled trials. Research examined temporary physiological imbalance by monitoring outcomes specifically tracking shifts in Systolic and Diastolic Blood Pressure (SBP/DBP) and monitoring the association with long-term events like stroke. These studies were evaluated in a broad range of adults, including those with and without elevated blood pressure.

Research highlights changes measured during the study period, with aggregated trial data describing patterns of changes measured in blood pressure biomarkers in specific participant groups. Some long-term data show patterns related to higher habitual potassium intake being associated with specific cardiovascular events. However, the evidence is limited and findings were mixed regarding the outcomes of the dual-mineral composition, as studies often focus on a single component.

Key Studies & References

  1. Calcium and Vitamin D Supplementation to Prevent Fractures in Adults: A Systematic Review and Meta-analysis
  2. Dietary Reference Intakes for Calcium and Vitamin D (Institute of Medicine)

Frequently Asked Questions (FAQ)

Common questions about Cal-K (FAQ)


Q: Is Cal-K the same type of drug as [Competitor Drug Name]?

Official documents classify Cal-K as a combination mineral supplement and electrolyte preparation. This places it within the general category of products intended to address specific nutrient needs. Regulatory information defines the product by its composition and intended use, rather than by direct comparison to other brands.


Q: What makes Cal-K different from other similar treatments?

According to official product information, the distinguishing characteristic of Cal-K is its dual-mineral composition. This formulation delivers two essential nutrients, Calcium (Ca) and Potassium (K), simultaneously. This approach targets patients who require comprehensive support for the status of both minerals.


Q: Is a headache a common side effect of Cal-K?

Headache has been reported in regulatory literature as an adverse reaction in association with the use of some mineral supplements. However, the official frequency of this symptom (whether it is considered common, uncommon, or rare) can vary depending on the product's specific formulation and labeling.


Q: Are there any long-term side effects associated with Cal-K use?

The official safety profile documents the risk of severe events such as hyperkalemia and gastrointestinal lesions that can occur during or after use. These documented risks are relevant to the product’s safety regardless of whether the use is short-term or extended. All known side effects are included in the official documentation.


Q: Does Cal-K interact with common vitamins like B12 or Vitamin D?

Official regulatory texts often establish a relationship between the Calcium component and the metabolism of Vitamin D. Critical drug interactions requiring mandatory action are typically not documented for Vitamin B12. The official product labeling contains the most specific guidance regarding the co-administration of supplements.


Q: Can Cal-K be taken with over-the-counter pain relievers like ibuprofen?

Regulatory documents contain warnings that taking the product with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as ibuprofen, increases the risk of developing hyperkalemia. This condition describes dangerously high levels of potassium in the blood.


Q: Are there any foods or drinks that should be avoided while using Cal-K?

Official documents state that the co-administration of certain products is restricted, as detailed in the warnings. Specifically, regulatory information cautions against using potassium-containing salt substitutes and other calcium supplements or antacids while using Cal-K.


Q: Can Cal-K affect the results of lab tests?

According to the official product information, Cal-K can potentially cause elevated serum levels of Calcium and Potassium. These increased levels may be detected and interfere with the results of certain blood and urine tests conducted by laboratories.


Q: Is Cal-K appropriate for people with kidney or liver issues?

Regulatory documents place a primary emphasis on caution for patients with impaired renal function (kidney issues). Official information specifies that rigorous monitoring of serum mineral levels is necessary for this group due to the potential high risk of hyperkalemia. Liver issues are not typically highlighted as a primary warning for this type of supplement.


Q: Is it normal to feel a bit tired when starting Cal-K?

Tiredness or generalized weakness is listed in the safety profile as a potential symptom of hyperkalemia. This condition is documented as a serious adverse reaction, caused by dangerously high levels of potassium in the blood.


Q: Is Cal-K considered to be a 'strong' medicine?

The formal classification of the product in regulatory documents is a mineral supplement and electrolyte preparation. This category is widely recognized for nutritional support and dietary management.


Q: Can Cal-K cause dependence or withdrawal symptoms?

Official regulatory texts consistently state that this product, as a mineral supplement, is generally not associated with the symptoms of dependence or withdrawal.


Q: Does Cal-K require any special monitoring while using it?

Official documents specify that the monitoring of serum mineral levels is mandated by regulatory agencies for certain at-risk populations. This mandatory monitoring applies to individuals with impaired renal function (kidney issues) and older adults.


Q: Can I crush or split Cal-K tablets?

Administration guidelines for solid oral dosage forms typically indicate that altering the tablet (crushing or splitting) should be avoided unless the tablet is specifically scored for that purpose. Altering the form may increase the risk of local gastrointestinal irritation.


Q: Why does the packaging for Cal-K have a warning about [a specific, but non-dosing, known warning]?

Regulatory documents include a detailed rationale that explains all mandatory warnings on the packaging. For this product, the rationale explains the specific reasons for caution against risks such as hyperkalemia or gastrointestinal lesions.


Q: Does alcohol consumption affect the safety of Cal-K?

While not always listed as a critical, life-threatening interaction, regulatory-aligned sources often include statements about exercising caution regarding alcohol intake. Excessive alcohol consumption can impact the body's mineral absorption and status while using a supplement.


Q: Does Cal-K have a risk of allergic reactions?

Yes, the official safety profile consistently documents the risk of hypersensitivity or allergic reactions. This risk applies to both the active mineral ingredients and any excipients (inactive ingredients) in the product.


Q: Can you use Cal-K if you have a history of [general disease, e.g., heart problems]?

The product is officially contraindicated (should not be used) in patients with pre-existing hyperkalemia, a condition that poses a specific risk to the cardiovascular system. Official warnings indicate the need for extreme caution when the product is used by patients with severe heart disease.


Q: Is Cal-K known to cause dry mouth?

Dry mouth has been reported as an adverse reaction in official literature in association with mineral supplements. Its frequency classification can vary depending on the product’s specific official label.


Q: What is the physical appearance of the Cal-K pill/tablet?

Official regulatory labels include a description of the final product's physical characteristics. This description details the tablet's size, shape, and specific color for product identification purposes.


Q: What does the patient leaflet say about using machinery while on Cal-K?

Official patient information is required to include a non-directive statement on whether the product is known to affect a person's ability to drive or operate machinery. This is included to ensure informed use of the product.


Q: Does Cal-K have a specific color or identifying mark?

Yes, official regulatory labels include a description of the final product’s physical attributes. This includes its specific color, shape, and any unique identifying imprints or scoring marks.


Q: What happens if Cal-K is exposed to heat or light?

Official storage guidelines indicate that the product must be stored at controlled room temperature. The guidelines also often mention that the product stability is maintained when protected from light and moisture.

How should Cal-K be stored and disposed of?

How to Store and Dispose of Cal-K

Official regulatory documents define strict storage and disposal requirements for Cal-K (oral calcium and potassium supplement).

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Container The container must be kept tightly closed when not in use.
Stability Any dose mixed with food or liquid must be used immediately and cannot be stored for later use.
Protection The product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired product should first be discarded using an official community drug take-back program. If this option is unavailable, the product may be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before disposal in the household trash. Identifying information must be removed from the container label prior to discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cal-K found in:

A-Z Index: